Estrogen promotes ER-negative tumor growth and angiogenesis through mobilization of bone marrow-derived monocytes

Cancer Research

Volumn 72, Issue 11, 2012, Pages 2705-2713

  Iyer, Vandana ^a   Klebba, Ina ^a   McCready, Jessica ^a   Arendt, Lisa M ^a   Betancur Boissel, Monica ^a   Wu, Meng Fen ^b   Zhang, Xiaomei ^b   Lewis, Michael T ^b   Kuperwasser, Charlotte ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR ALPHA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BREAST CANCER; BREAST CARCINOGENESIS; CELL POPULATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; BONE MARROW CELLS; BREAST NEOPLASMS; CELL MOVEMENT; ESTRADIOL; FEMALE; HUMANS; MICE; MICE, KNOCKOUT; MONOCYTES; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, ESTROGEN;

EID: 84861871155     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3287     Document Type: Article

References (27)

1. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17-35. (Pubitemid 23269068)
2. Swain SM. Tamoxifen for patients with estrogen receptor-negative breast cancer. J Clin Oncol 2001;19 18 Suppl:93S-7S. (Pubitemid 32880089)
3. Rebbeck TR. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2000;18 21 Suppl:100S-3S.
4. Nissen-Meyer R. Prophylactic endocrine treatment in carcinoma of the breast. Clin Radiol 1964;15:152-60.
5. Gelmann EP. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin Oncol 1997;24 1 Suppl 1:S1.
6. Garcia-Leiva J, Gamboa-Dominguez A, Ceron-Lizarraga T, Morales-Espinosa D, Meza-Junco J, Arrieta O. Response of negative estrogen-receptor hepatocarcinoma to tamoxifen, and survival of non-resectable patients. Ann Hepatol 2006;5:263-7. (Pubitemid 44904539)
7. Chlebowski RT, Schwartz AG,Wakelee H, Anderson GL, Stefanick ML, Manson JE, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009;374:1243-51.
8. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci U S A 1993;90:11162-6. (Pubitemid 23354389)
9. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002;296:920-2. (Pubitemid 34464899)
10. Shim GJ, Wang L, Andersson S, Nagy N, Kis LL, Zhang Q, et al. Disruption of the estrogen receptor beta gene in mice causes myeloproliferative disease resembling chronic myeloid leukemia with lymphoid blast crisis. Proc Natl Acad Sci U S A 2003;100:6694-9. (Pubitemid 36675339)
11. Karas RH, Schulten H, Pare G, Aronovitz MJ, Ohlsson C, Gustafsson JA, et al. Effects of estrogen on the vascular injury response in estrogen receptor alpha, beta (double) knockout mice. Circ Res 2001;89:534-9. (Pubitemid 34133991)
12. Johns A, Freay AD, Fraser W, Korach KS, Rubanyi GM. Disruption of estrogen receptor gene prevents 17 beta estradiol-induced angiogenesis in transgenic mice. Endocrinology 1996;137:4511-3. (Pubitemid 26321904)
13. Koerner F, Oyama T, Kurosumi M, Maluf H. Ovarian hormone receptors in human mammary stromal cells. J Steroid Biochem Mol Biol 2000;78:285-90.
14. Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor transcription and transactivation: estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res 2000;2:335-44. (Pubitemid 32223616)
15. Dvorak H, Flier J, Frank H. Tumours- wounds that do not heal-similarities between tumour stroma generation and wound healing. N Engl J Med 1986;315:1650-9. (Pubitemid 17052899)
16. Gupta PB, Proia D, Cingoz O, Weremowicz J, Naber SP, Weinberg RA, et al. Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res 2007;67:2062-71. (Pubitemid 46424224)
17. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008;66:1-9. (Pubitemid 351324128)
18. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006;66:11238-46. (Pubitemid 46009952)
19. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-6. (Pubitemid 43121975)
20. Arendt LM, Rudnick JA, Keller PJ, Kuperwasser C. Stroma in breast development and disease. Semin Cell Dev Biol 2010;21:11-8.
21. Losordo DW, Isner JM. Estrogen and angiogenesis: a review. Arterioscler Thromb Vasc Biol 2001;21:6-12. (Pubitemid 32061922)
22. Suriano R, Chaudhuri D, Johnson RS, Lambers E, Ashok BT, Kishore R, et al. 17Beta-estradiol mobilizes bone marrow-derived endothelial progenitor cells to tumors. Cancer Res 2008;68:6038-42.
23. Schledzewski K, Falkowski M, Moldenhauer G, Metharom P, Kzhyshkowska J, Ganss R, et al. Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis. J Pathol 2006;209:67-77.
24. Heissig B, Hattori K, Dias S, FriedrichM, Ferris B, Hackett NR, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002; 109:625-37. (Pubitemid 34628725)
25. Hall JM, Korach KS. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol 2003;17:792-803. (Pubitemid 36539573)
26. Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, et al. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Invest 2011;121:1969-73.
27. Calippe B, Douin-Echinard V, Delpy L, Laffargue M, Lelu K, Krust A, et al. 17Beta-estradiol promotes TLR4-triggered proinflammatory mediator production through direct estrogen receptor alpha signaling in macrophages in vivo. J Immunol 2010;185:1169-76.